Institute of Cancer Research: International Trial Shows Combination Immunotherapy Treatment Significantly Improves Survival in High-Risk Kidney Cancer Patients
October 21, 2025
October 21, 2025
LONDON, England, Oct. 21 -- The Institute of Cancer Research issued the following news:
* * *
International trial shows combination immunotherapy treatment significantly improves survival in high-risk kidney cancer patients
Combination immunotherapy treatment significantly improves disease-free survival following surgery in patients with the most common type of kidney cancer, according to new research.
Results from the Phase III RAMPART trial w . . .
* * *
International trial shows combination immunotherapy treatment significantly improves survival in high-risk kidney cancer patients
Combination immunotherapy treatment significantly improves disease-free survival following surgery in patients with the most common type of kidney cancer, according to new research.
Results from the Phase III RAMPART trial w . . .